Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2015

GlobeNewswire August 13, 2015

Hemispherx Biopharma Board Appoints New President

GlobeNewswire August 13, 2015

Hemispherx Expands Its Collaboration With Emerge Health for the Commercialization of Alferon in Australia and New Zealand

GlobeNewswire August 11, 2015

Hemispherx Enters Into an Agreement With myTomorrows for an Early Access Program for Rintatolimod in Europe

GlobeNewswire August 10, 2015

Hemispherx Biopharma to Host Stockholder Open House at Manufacturing and Research Facility in New Jersey

GlobeNewswire July 27, 2015

Hemispherx Biopharma Announces Final Approval of Securities Class Action Settlement

GlobeNewswire July 23, 2015

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx Biopharma, Inc. Class Action and Settlement Hearing -- HEB

GlobeNewswire July 17, 2015

Hemispherx Biopharma Europe N.V./S.A. Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection(R) for Treatment of Middle East Respiratory Syndrome (MERS)

GlobeNewswire July 15, 2015

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx Biopharma, Inc. Class Action and Settlement Hearing - HEB

GlobeNewswire July 10, 2015

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx Biopharma, Inc. Class Action and Settlement Hearing -- HEB

GlobeNewswire June 30, 2015

Hemispherx Receives the European Patent Office Examining Division's Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen(R) Formulations

GlobeNewswire June 25, 2015

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx Biopharma, Inc. Class Action and Settlement Hearing - HEB

GlobeNewswire June 11, 2015

Hemispherx Biopharma Announces Preliminary Approval of Securities Class Action Settlement

GlobeNewswire June 4, 2015

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx Biopharma, Inc. Class Action and Settlement Hearing - HEB

GlobeNewswire June 2, 2015

Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease (EVD)

GlobeNewswire May 26, 2015

Hemispherx to Present at the Marcum Microcap Conference in New York

GlobeNewswire May 20, 2015

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx Biopharma, Inc. Class Action and Settlement Hearing - HEB

GlobeNewswire May 18, 2015

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2015

GlobeNewswire May 13, 2015

Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

GlobeNewswire May 11, 2015

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx Biopharma, Inc. Class Action and Settlement Hearing - HEB

GlobeNewswire May 7, 2015